1 Polygenic prediction of breast cancer: comparison of 2 genetic predictors and implications for screening

3

4 Kristi Läll MSc^{1,5}, Maarja Lepamets MSc¹, Marili Palover MSc¹, Tõnu Esko PhD^{1,2}, Andres
5 Metspalu PhD, MD¹, Neeme Tõnisson¹, Peeter Padrik PhD^{3,4}, Reedik Mägi PhD¹, Krista
6 Fischer PhD¹

7 Affiliations

- 8 1. Estonian Genome Center, Institute of Genomics, University of Tartu, Estonia
- 9 2. Broad Institute, Cambridge, USA
- 10 3. Institute of Clinical Medicine, University of Tartu, Estonia
- 11 4. Cancer Center, Tartu University Hospital, Tartu, Estonia
- 12 5. Institute of Mathematics and Statistics, University of Tartu, Estonia

13

14 *Correspondence:*

15 Kristi Läll

16 Address: Riia 23b, Tartu, 51010, Estonia

17 E-mail: kristi.lall@ut.ee

18 Phone: +372 737 4042

19

20 Abstract

21 Background

22 Published genetic risk scores for breast cancer (BC) so far have been based on a
23 relatively small number of markers and are not necessarily using the full potential of large-
24 scale Genome-Wide Association Studies. This study aims to identify an efficient polygenic
25 predictor for BC based on best available evidence and to assess its potential for personalized
26 risk prediction and screening strategies.

27 Methods

28 Four different genetic risk scores (two already published and two newly developed)
29 and their combinations (metaGRS) are compared in the subsets of two population-based
30 biobank cohorts: the UK Biobank (UKBB, 3157 BC cases, 43,827 controls) and Estonian
31 Biobank (EstBB, 317 prevalent and 308 incident BC cases in 32,557 women). In addition,
32 correlations between different genetic risk scores and their associations with BC risk factors
33 are studied in both cohorts.

34 Results

35 The metaGRS that combines two genetic risk scores (metaGRS₂ - based on 75 and
36 898 Single Nucleotide Polymorphisms, respectively) has the strongest association with
37 prevalent BC status in both cohorts. One standard deviation difference in the metaGRS₂
38 corresponds to an Odds Ratio = 1.6 (95% CI 1.54 to 1.66, $p = 9.7 \times 10^{-135}$) in the UK Biobank
39 and accounting for family history marginally attenuates the effect (Odds Ratio = 1.58, 95%
40 CI 1.53 to 1.64, $p = 9.1 \times 10^{-129}$). In the EstBB cohort, the hazard ratio of incident BC for the
41 women in the top 5% of the metaGRS₂ compared to women in the lowest 50% is 4.2 (95% CI
42 2.8 to 6.2, $p = 8.1 \times 10^{-13}$). The different GRSs are only moderately correlated with each other

43 and are associated with different known predictors of BC. The classification of genetic risk
44 for the same individual may vary considerably depending on the chosen GRS.

45 **Conclusions**

46 We have shown that metaGRS₂ that combines on the effects of more than 900 SNPs
47 provides best predictive ability for breast cancer in two different population-based cohorts.
48 The strength of the effect of metaGRS₂ indicates that the GRS could potentially be used to
49 develop more efficient strategies for breast cancer screening for genotyped women.

50 **Key words:** Polygenic risk score, Genetic predisposition to disease, Breast cancer, Risk
51 stratification, Personalized medicine

52 **Background**

53 Breast cancer (BC) is the most frequent cancer among women in the world, being also
54 the second leading cause of cancer death in women in more developed regions after lung
55 cancer¹. As early diagnosis for BC could lead to successful treatment and good prognosis for
56 recovery, it is important to develop efficient risk prediction algorithms that aid to identify
57 high-risk individuals. Although many countries have implemented mammography screening
58 programs, they mostly apply to all women in certain age categories without any additional
59 stratification by other risk factors. However, the benefits of such screening programs are
60 often debated. Existing tools to assess BC risk²⁻⁴ are often not systematically used in
61 screening due to insufficient up-to-date risk factor's information. Also, they only capture the
62 heritable component either in the form of family history or using the information on rare
63 genetic variants (BRCA1/2).

64 It has been estimated in twin studies that the heritability of breast cancer ranges from
65 20 to 30%⁵. However, only 5%–10% of BC cases have a strong inherited component

66 identified in a form of rare genetic variants⁶, indicating that in addition there should be a
67 considerable polygenic component in the disease liability. This is also supported by the
68 results of large genome-wide association studies (GWAS) – more than 100 genomic loci have
69 been identified as being associated with BC in Europeans⁷.

70 Based on the GWAS results, several efficient polygenic risk scores (GRS) have been
71 developed for common complex diseases that in many cases can be used to improve the
72 existing risk prediction algorithms^{8–11}. It is natural to expect that a similar GRS for BC may
73 aid risk prediction in clinical practice.

74 So far, several studies have combined the SNPs with established genome-wide
75 significance in a GRS for BC. Sieh *et al*¹² used 86 SNPs and Mavaddat *et al*¹³ 77 SNPs to
76 calculate a GRS, both showing a strong effect of the score in predicting future BC cases. Few
77 studies have also demonstrated the incremental value of adding GRS to proposed BC
78 prediction algorithms^{14,15}. Although several different GRSs have been proposed for BC risk
79 prediction, no head-to-head comparison of the scores has been found in the literature. It has
80 also not been assessed, whether the number of SNPs in the GRS could be increased. The
81 latter was also problematic due to unavailability of summary statistics from large-scale
82 GWASs.

83 In 2017, the large scale GWAS by Michailidou *et al*⁷ released summary statistics for
84 around 11.8 million genetic variants. Almost at the same time, UK Biobank released their
85 GWAS results for BC for ~10.8 million SNPs. As evidence from studies on other common
86 complex diseases indicates that predictive ability of a GRS can improve by adding the effects
87 of a large number of independent SNPs in addition to the ones with established genome-wide
88 significance, we intend to explore this approach using both summary files.

89 **Methods**

90 **Study cohorts**

91 In the present analysis, the data of 32,557 female participants of the Estonian Biobank
92 (EstBB)¹⁶ has been used, with 317 prevalent and 308 incident cases of BC. Incident disease
93 data was obtained from linkages with the Estonian Health Insurance Fund, Estonian Causes
94 of Death Registry and Estonian Cancer Registry (latest update in December 2015).

95 We have also analyzed the data of 46,984 women (incl 3,157 BC cases) of European
96 ancestry from the UK Biobank¹⁷ who passed the main quality control and were not included
97 in the UKBB breast cancer GWAS¹⁸.

98 More details about cohorts can be found in the Additional File 2 and overview of the
99 characteristics of the cohorts is given in the Additional File 1, Table S1.

100 **Statistical Methods**

101 **General concept of Genetic Risk Scores (GRS)**

102 The general definition of a GRS is based on the assumption that the polygenic
103 component of the trait (e.g. disease risk) can be approximated by a linear combination of k
104 independent SNPs

$$GRS_i = \sum_{j=1}^k \beta_j X_{ij}$$

105 where β_j is the weight of each SNP and X_{ij} represents the number of risk alleles for $j - th$
106 SNP ($j = 1, \dots, k$) for the $i - th$ individual, ($i = 1, \dots, n$). Typically the estimated (logistic)
107 regression coefficients from a large-scale GWAS meta-analysis are used as weights β_j .

Published versions of GRS can be divided to two main categories. We call a GRS *multigenic*, if the number of SNPs (k) is relatively small, containing only the SNPs with established genome-wide significance from a GWAS. A *polygenic* GRS may contain a large number of SNPs (often $k > 1000$) and is either based on all available independent SNPs (with pairwise correlation not exceeding a pre-defined threshold) or the ones that satisfy some p-value threshold (often ≥ 0.05).

In the present paper, we will compute two multigenic and two polygenic GRSs, whereas the polygenic GRSs are developed using the PRSice software¹⁹.

Computation of multigenic and polygenic GRSs and analysis of their association with prevalent breast cancer

First we calculate two previously published multigenic GRSs for the EstBB data – both scores contain only those SNPs from the originally published versions that are available with acceptable imputation accuracy in the EstBB.

1. The score denoted by **GRS₇₀**, based on Sieh *et al*¹² (70 SNPs out of 86 were available).
2. The score **GRS₇₅**, based on the 75 SNPs of the 77-SNP score by Mavaddat *et al*¹³.

Next, two polygenic GRSs were developed. For both GRSs, first a set of SNPs was created so that: a) GWAS summary statistics are available for the entire set; b) the SNPs are genotyped or imputed with an acceptable quality in the EstBB; c) the SNPs are independent – the pairwise correlation does not exceed a pre-specified threshold (details on SNP selection provided in the Additional File 2). For the final selection of the p-value threshold for the SNPs to be included in the GRS, age-adjusted logistic regression model comparing prevalent BC cases and 2000 randomly chosen controls in the EstBB cohort was used and the

score with the smallest p-value for the GRS-phenotype association was selected. The resulting polygenic scores are:

3. The score **GRS_{ONCO}**, based on the summary statistics of the Breast Cancer Association Consortium meta-analysis of BC with 122,977 cases and 105,974 controls⁷.
4. The score **GRS_{UK}**, based on the summary statistics of the GWAS conducted on the UK Biobank data (comparing 7,480 BC cases and 329,679 controls including both men and women¹⁸). The reported linear regression coefficients were transformed into corresponding log odds ratios, following the rules described by Lloyd-Jones *et al*²⁰, before using them as weights in the GRS.
5. Thereafter, Pearson coefficients of correlation between different GRSs were calculated. The GRSs were combined into three different versions of metaGRS, following the ideas by Inouye *et al*²¹: **metaGRS₄** as the weighted average of all four GRSs, **metaGRS₃** as the weighted average of three GRSs with the strongest association with incident BC and finally **metaGRS₂** based on top two predicting GRSs. As weights to construct metaGRS, log(odds ratios) of GRSs from training set from logistic regression model were used.

Finally, the UK biobank data was used to address the attenuation of GRS' effect while accounting for family history of BC and to study associations between BC risk factors and GRSs. While modelling in UK biobank, age at recruitment and 15 principal components are included in the model.

Analysis of the GRS effects on incident BC

All 7 GRSs were evaluated in the analysis of incident BC in 30240 women from the EstBB cohort who did not have an existing BC diagnosis at recruitment and were not included in the case-control set used to select the best polygenic GRSs. Cox proportional

hazard models were used to estimate the crude and adjusted Hazard Ratios (HR) corresponding to one standard deviation (SD) of the GRS. To properly account for left-truncation in the data, age of the participant was used as timescale in the analyses. To assess the incremental value of GRSs when added to other known risk factors, the models were additionally adjusted for the absolute risk estimates from the NCI Breast Cancer assessment tool^{2,22}, based on age, race, age at menarche and age at first live birth of the participant. Other possible risk factors such as number of biopsies were set as unknown. Harrell's c-statistic to characterize the discriminative ability of each GRS and their incremental value compared to NCI's Breast Cancer assessment tool absolute risk estimates alone were computed. Hazard ratios for GRS top quintile and top 5% percentile compared to average and low GRS categories were reported. Cumulative incidence estimates were computed with Aalen-Johansen estimator to account for competing risk.

Finally, associations between GRSs and variables related to female's reproductive health and BC risk factors are explored using linear, logistic or Cox regression models depending on the type of dependent variable in both EstBB and UKBB cohorts (more details in the Additional File 2).

Results

GRSs association with prevalent breast cancer

Both GRS₇₀ and GRS₇₅ were significantly associated with prevalent BC status in the case-control subset of the EstBB cohort, with corresponding Odds Ratio(OR) estimates per one SD of the GRS being 1.27 (95% CI 1.13 to 1.45, $p = 1.4 \times 10^{-4}$) and 1.38 (95% CI 1.22 to 1.57, $p = 5.3 \times 10^{-7}$), respectively. Of all polygenic GRSs, the strongest association was observed for GRS_{ONCO} with p-value threshold $p < 5 \times 10^{-4}$ for SNP inclusion (898 SNPs). This

resulted in OR = 1.44 (95% CI 1.27 to 1.64, $p = 1 \times 10^{-8}$) per one SD of the GRS. The best version of GRS_{UK} included 137 SNPs that satisfied inclusion threshold $p < 5 \times 10^{-5}$ and resulted in OR = 1.34 (95% CI 1.18 to 1.52, $p = 5.5 \times 10^{-6}$). Similar effect sizes for all four GRSs were observed in the UKBB cohort (Table S2). Detailed results on GRS-outcome associations in EstBB with different p-value thresholds for SNP inclusion can be seen in Additional File 2, Figure S1.

Association of incident breast cancer and GRSs

Out of four studied GRSs, GRS_{UK} has the weakest and GRS₇₅ the strongest association with incident BC (Table 1) in the EstBB, both in terms of the p-value as well as the Harrell's c-statistic. All metaGRSs have stronger association with incident BC than original scores alone. However, when GRS_{ONCO} and GRS₇₅ are already combined into metaGRS₂, no additional gain is seen from adding GRS_{UK} and/or GRS₇₀ to the score. Therefore, we chose metaGRS₂ for further assessment of its properties. While a predictive model capturing the effect of the NCI risk estimates resulted in the Harrell's c-statistic of 0.677, it was increased to 0.715 (by 3.8%) when also metaGRS₂ was added to the model.

Table 1. Analysis results for incident breast cancer in EstBB using different GRSs and metaGRSs.

	Score	NCI	GRS ₇₀	GRS ₇₅	GRS _{UK}	GRS _{ONCO}	metaGRS ₄	metaGRS ₃	metaGRS ₂
HR* per 1 SD		1.7	1.44	1.59	1.23	1.52	1.61	1.65	1.65
with 95% CI		1.52-1.9	1.29-1.61	1.42-1.78	1.1-1.38	1.35-1.7	1.43-1.80	1.47-1.85	1.48-1.86
p-value		1.4×10^{-20}	3.2×10^{-10}	1.1×10^{-15}	4×10^{-4}	1.7×10^{-12}	4.4×10^{-16}	1.43×10^{-17}	7.6×10^{-18}

Harrell's c –	0.677	0.603	0.627	0.561	0.615	0.634	0.637	0.636
statistic								
Harrell's c –		0.701	0.708	0.684	0.705	0.715	0.716	0.715
statistic	NA	($\Delta=0.024$)	($\Delta=0.031$)	($\Delta=0.007$)	($\Delta=0.028$)	($\Delta=0.038$)	($\Delta=0.039$)	($\Delta=0.038$)
NCI+GRS								

196 Legend: Harrell's c-statistics for all versions of genetic risk scores and National Cancer
197 Institute Breast Cancer Assessment Tool risk estimates (based on age, race, age at menarche
198 and age at first live birth) were calculated. Δ -GRS added improvement in c-statistics
199 compared to NCI alone. *Hazard ratio for developing breast cancer is given per 1 SD
200 increase. CI = confidence intervals; GRS = genetic risk score; HR = Hazard ratio; NCI –
201 National Cancer Institute Breast Cancer assessment tool estimates calculated with R package
202 BCRA.

The score metaGRS₂ and its potential for personalized breast cancer risk prediction

Figure 1. Cumulative incidence of BC in metaGRS₂ categories among women within age 30-75 years.

Legend: Cumulative incidence accounting for competing risks. Hazard ratios (HR) correspond to the comparison of several categories with the lowest quartile of metaGRS₂.

Women in the highest quartile of metaGRS₂ distribution have 3.40 (95% CI 2.36 to 4.89) times higher hazard of developing BC than women in the lowest quartile. When the top

quartile is further split into smaller percentiles (as seen on Figure 1), a strong risk gradient is seen also within this quartile. Namely, women in the top 5% of the metaGRS₂ distribution have a Hazard Ratio (HR) of 4.79 (95% CI 3.02 to 7.58) for incident BC compared to women in the lowest quartile, whereas HR = 4.20 (95% CI 2.84 to 6.23) for women in the top 5% compared to all women with metaGRS₂ below the median. When the highest 5% percentile is compared with the rest of the cohort (women below the 95th percentile of metaGRS₂), about three times higher hazard (HR = 2.73, 95% CI 1.92 to 3.90) is found.

As seen from Figure 1, the cumulative BC incidence by the age of 70 is estimated to be 12% (95% CI 7.7% to 16.3%) for women in the top 5% percentile of metaGRS₂, 8.3% (95% CI 5.6% to 11.0%) for those between 85%-95% percentiles and 7.4% (95% CI 4.85% to 10.0%) for the women in 75%-85% percentiles. Cumulative BC incidence in the third, second and first quartile of the metaGRS₂ distribution is estimated to be 5.8% (95% CI 4.4% to 7.3%), 3.6% (95% CI 2.4% to 4.8%) and 2.4% (95% CI 1.4% to 3.3%), respectively. No significant difference in BC hazard is seen between the two lowest quartiles ($p = 0.26$), with both of them having considerably lower incidence level than the cohort average (overall cumulative BC incidence estimated as 5.1% by the age of 70, 95% CI 4.5% to 5.8%).

229 Correlation of GRSs

230

231 **Figure 2.** Division of Estonian Biobank women according to their genetic risk category.

232 *Legend: Women, who belong to top 5% at least with one out of the three genetic risk scores*
 233 *(GRSs: GRS_{ONCO} , GRS_{UK} , or GRS_{75}), are represented on this graph. Number of women, who*
 234 *belong to top 5% only with one score, two scores or all three scores are given. Percentages*
 235 *are given per entire cohort.*

236 The correlations between seven scores varied between 0.3 to 1 (see Figure S2). While
 237 dividing individuals into 2 categories (“non-high” – $GRS < 95$ th percent and “high” – GRS in

top 5%) based on three GRSs (GRS_{UK} , GRS_{ONCO} or GRS_{75}), 87.7% (28547) of women were assigned to non-high category with all three scores. However, 12.4% (4010) of women belong to high category with at least one GRS. 0.33% (109) of women belonged to top 5% with all three scores compared to ~10% (3240) of the women, who belonged into high category only with one score (Figure 2).

Associations of GRSs and other genetic and non-genetic predictors of breast cancer

Both family history as well as GRSs were strongly associated with BC status in UKBB, while the effects of GRSs were attenuated by less than 1% while adjusting for family history (Additional File 1, Table S2). Known BC risk factors were only weakly associated with in both UKBB and EstBB cohorts (Additional File 1, Table S3-S4). BMI and waist circumference were negatively associated with GRS_{UK} in both EstBB and UKBB, the association in EstBB was stronger for women under 50 years of age. Smoking status was positively associated with all GRSs except GRS_{UK} only in EstBB data. Age at menopause was associated with some GRSs in both cohorts but the effects were in opposite direction. No GRS showed association with any other type of cancer or overall mortality.

Discussion

We demonstrate that a metaGRS that combines a multigenic and a polygenic GRS for breast cancer, metaGRS₂, performs better than using either one of the previously published multigenic GRSs and also better than the best polygenic GRS alone. While in average about 5% of women in the EstBB cohort (as well as in the Estonian population) have been diagnosed with BC by the age of 70, women in the highest five percentiles of the metaGRS₂ distribution have reached the same cumulative risk level (5%, 95% CI 2.1% to 7.8%) by the age of 49, thus more than 20 years earlier. It is also notable that women with

metaGRS₂ level below median reach such risk level (4.6%, 95% CI 3.6% to 5.6%) only by age of 79, thus almost 10 years later. This finding suggests that the polygenic risk estimate based on metaGRS₂ could be an efficient tool for risk stratification in clinical practice, for targeted screening and prevention purposes.

Given that the potential benefits of non-selective BC screening within certain age categories (compared to potential harm from over diagnosis) are under serious discussion in medical community²³, personalized approaches based on individual risk levels deserve further assessment. Ideally, those should integrate available information from clinical risk factors and also genetic information. The latter could include both moderate- and high-penetrance germline mutation testing, as well as polygenic risk scores. That approach is also supported by our findings, where considerable increase in c-statistics were observed while combining polygenic risk scores and NCI estimates together.

However, while incorporating a GRS in clinical BC prediction, one should keep in mind that a GRS represents a mixture of different pathways, but is still not likely to capture the heritable component completely. As our findings indicate that a GRS and family history have independent predictive effects on BC risk, accounting for individual's genetic information and family history simultaneously in risk estimation could be recommended.

As depending on a GWAS that is used as a basis, different (and not necessarily highly correlated) GRSs can be produced, it is expected that those GRSs might emphasize the effects of different biological pathways. This hypothesis seems plausible in the light of several associations found between different GRSs and BC risk factors.

The fact that a metaGRS performs better than alternatives, suggests that the SNPs that are included in the multigenic GRS₇₅ are potentially representing genetic pathways with stronger effect on the disease risk and the combined score will give them a stronger weight

than the polygenic GRS alone. However, it also indicates that the SNPs included in the polygenic GRS_{ONCO} - but not in the GRS₇₅ - have some predictive power and therefore one should not completely ignore them in an optimal GRS.

It remains an open question whether it is always the best practice to use metaGRS instead of several different genetic risk scores – if one can pinpoint biological mechanisms behind different scores, more optimal preventive strategies could be chosen. Still, until we are unable to convincingly link different GRSs with specific preventive measures, targeted prevention should be based on a GRS with the best possible overall predictive ability, such as the metaGRS₂ proposed here.

One should also keep in mind that besides GRS there are genetic mutations such as BRCA1/2 known to be associated with very high familial BC risk. Therefore, in practice, any genomic risk stratification should include search for high-risk genetic variants, or moderate risk variants, as well, if possible. In the high-risk mutation carriers, the clinical management could be based on the specific genetic (mendelian) variants, or if deemed useful in the future, a combination of mendelian variants and GRS levels, but it definitely needs further studies.

Conclusions

In summary, our results show that an efficient polygenic risk estimate enables to identify strata with more than four-fold differences in BC incidence. This definitely calls for the development of personalized screening and prevention strategies that incorporate the GRS information, having the potential to considerably increase the benefits of nation-wide screening programs and reduce the existing controversies on their efficacy. However, one should be aware of the fact that a GRS is not uniquely defined – as more research accumulates, more efficient polygenic predictors could be developed that may re-categorize some previously stratified individuals into high or low risk groups. In addition, a GRS should

ideally be combined with information on other genetic and non-genetic risk factors for best possible accuracy in risk assessment.

List of abbreviations

BC – Breast Cancer, **GWAS** – Genome-Wide Association Study, **GRS** – Genetic Risk Score, **EstBB** – Estonian Biobank, **UKBB** – UK Biobank, **SNP** – Single Nucleotide Polymorphism, **metaGRS** – combination of several genetic risk scores, number in subscript indicates the number of original GRSs included, **SD** – Standard Deviation, **HR** - Hazard Ratio, **OR** - Odds Ratio, **NCI** – National Cancer Institute Breast Cancer, **CI** - Confidence Intervals

Declarations

Ethics approval and consent to participate

EstBB: All human research was approved by the Research Ethics Committee of the University of Tartu (approval 234/T-12), and conducted according to the Declaration of Helsinki. All participants provided written informed consent to participate in the Estonian Biobank.

UKBB: The UK Biobank study was approved by the North West Multi-Centre Research Ethics Committee (reference for UK Biobank is 16/NW/0274). All participants provided written informed consent to participate in the UK Biobank study.

Consent for publication

Not applicable.

Availability of data and material

We do not have ethical approval to share individual level genotype and phenotype data for Estonian Biobank. The data from UK Biobank were used under licence for the current study,

and so are not publicly available. Researchers interested in Estonian Biobank can request the access here: <https://www.geenivaramu.ee/en/access-biobank> and access to UK Biobank can be requested here <http://www.ukbiobank.ac.uk/resources/>.

Competing interests

The authors declare that they have no competing interests.

Funding

EGCUT was supported by Estonian Research Council [IUT20-60, IUT24-6, PUT1660 to T.E and PUT1665 to K.F.; European Union Horizon 2020 [692145]; European Union through the European Regional Development Fund [2014-2020.4.01.15-0012 GENTRANSMED] and National Programme for Addressing Socio-Economic Challenges through R&D (RITA).

Acknowledgements

This research has been conducted using the UK Biobank Resource under Application Number 17085.

References

1. International Agency for Research on Cancer. GLOBOCAN 2012:Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed May 9, 2018.
2. National Cancer Institute. Breast Cancer Risk Assessment Tool. <https://www.cancer.gov/bcrisktool/Default.aspx>. Published 2011. Accessed May 2, 2018.
3. Hippisley-Cox J, Coupland C. Development and validation of risk prediction

- 354 algorithms to estimate future risk of common cancers in men and women: prospective
355 cohort study. *BMJ Open*. 2015;5(3):e007825. doi:10.1136/bmjopen-2015-007825
- 356 4. Lee AJ, Cunningham AP, Kuchenbaecker KB, Mavaddat N, Easton DF, Antoniou AC.
357 BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour
358 pathology and web interface. *Br J Cancer*. 2014;110(2):535-545.
359 doi:10.1038/bjc.2013.730
- 360 5. Moller S, Mucci LA, Harris JR, et al. The Heritability of Breast Cancer among Women
361 in the Nordic Twin Study of Cancer. *Cancer Epidemiol Biomarkers Prev*.
362 2016;25(1):145-150. doi:10.1158/1055-9965.EPI-15-0913
- 363 6. Apostolou P, Fostira F. Hereditary breast cancer: the era of new susceptibility genes.
364 *Biomed Res Int*. 2013;2013:747318. doi:10.1155/2013/747318
- 365 7. Michailidou K, Lindström S, Dennis J, et al. Association analysis identifies 65 new
366 breast cancer risk loci. *Nature*. 2017;551(7678):92-94. doi:10.1038/nature24284
- 367 8. Läll K, Mägi R, Morris A, Metspalu A, Fischer K. Personalized risk prediction for
368 type 2 diabetes: the potential of genetic risk scores. *Genet Med*. 2017;19(3):322-329.
369 doi:10.1038/gim.2016.103
- 370 9. Abraham G, Havulinna AS, Bhalala OG, et al. Genomic prediction of coronary heart
371 disease. *Eur Heart J*. 2016;37(43):3267-3278. doi:10.1093/eurheartj/ehw450
- 372 10. Power RA, Steinberg S, Bjornsdottir G, et al. Polygenic risk scores for schizophrenia
373 and bipolar disorder predict creativity. *Nat Neurosci*. 2015;18(7):953-955.
374 doi:10.1038/nn.4040
- 375 11. Krapohl E, Patel H, Newhouse S, et al. Multi-polygenic score approach to trait

- 376 prediction. *Mol Psychiatry*. August 2017. doi:10.1038/mp.2017.163
- 377 12. Sieh W, Rothstein JH, McGuire V, Whittemore AS. The Role of Genome Sequencing
378 in Personalized Breast Cancer Prevention. *Cancer Epidemiol Biomarkers Prev*.
379 2014;23(11):2322-2327. doi:10.1158/1055-9965.EPI-14-0559
- 380 13. Mavaddat N, Pharoah PDP, Michailidou K, et al. Prediction of breast cancer risk based
381 on profiling with common genetic variants. *J Natl Cancer Inst*. 2015;107(5).
382 doi:10.1093/jnci/djv036
- 383 14. Maas P, Barrdahl M, Joshi AD, et al. Breast Cancer Risk From Modifiable and
384 Nonmodifiable Risk Factors Among White Women in the United States. *JAMA Oncol*.
385 2016;2(10):1295. doi:10.1001/jamaoncol.2016.1025
- 386 15. Li H, Feng B, Miron A, et al. Breast cancer risk prediction using a polygenic risk score
387 in the familial setting: a prospective study from the Breast Cancer Family Registry and
388 kConFab. *Genet Med*. 2017;19(1):30-35. doi:10.1038/gim.2016.43
- 389 16. Leitsalu L, Haller T, Esko T, et al. Cohort Profile: Estonian Biobank of the Estonian
390 Genome Center, University of Tartu. *Int J Epidemiol*. February 2014:dvt268-.
391 doi:10.1093/ije/dvt268
- 392 17. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for
393 identifying the causes of a wide range of complex diseases of middle and old age.
394 *PLoS Med*. 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779
- 395 18. Ben Neale Lab. Rapid GWAS of thousands of phenotypes for 337,000 samples in the
396 UK Biobank — Neale lab. [http://www.nealelab.is/blog/2017/7/19/rapid-gwas-of-](http://www.nealelab.is/blog/2017/7/19/rapid-gwas-of-thousands-of-phenotypes-for-337000-samples-in-the-uk-biobank)
397 [thousands-of-phenotypes-for-337000-samples-in-the-uk-biobank](http://www.nealelab.is/blog/2017/7/19/rapid-gwas-of-thousands-of-phenotypes-for-337000-samples-in-the-uk-biobank). Published 2017.
398 Accessed May 2, 2018.

- 399 19. Euesden J, Lewis CM, O'Reilly PF. PRSice: Polygenic Risk Score software.
400 *Bioinformatics*. 2015;31(9):1466-1468. doi:10.1093/bioinformatics/btu848
- 401 20. Lloyd-Jones LR, Robinson MR, Yang J, Visscher PM. Transformation of Summary
402 Statistics from Linear Mixed Model Association on All-or-None Traits to Odds Ratio.
403 *Genetics*. 2018;208(4):1397-1408. doi:10.1534/genetics.117.300360
- 404 21. Inouye M, Abraham G, Nelson CP, et al. Genomic risk prediction of coronary artery
405 disease in nearly 500,000 adults: implications for early screening and primary
406 prevention. *bioRxiv*. January 2018:250712. doi:10.1101/250712
- 407 22. Zhang F. BCRA: Breast Cancer Risk Assessment. 2018. [https://cran.r-](https://cran.r-project.org/package=BCRA)
408 [project.org/package=BCRA](https://cran.r-project.org/package=BCRA).
- 409 23. Autier P, Boniol M, Koechlin A, Pizot C, Boniol M. Effectiveness of and
410 overdiagnosis from mammography screening in the Netherlands: population based
411 study. *BMJ*. 2017;359:j5224. doi:10.1136/BMJ.J5224

412 Additional files

413 In the file “Additional file 1” are four Supplementary Tables in *.xlsx format. Tables are
414 labeled “S. Table 1-4”. The information included is following:

415 S. Table 1. Cohort characteristics of UK Biobank and Estonian Biobank.

416 S. Table 2. Associations of breast cancer and standardized GRSs in the UK Biobank (with
417 and without adjustment of family history) and in Estonian Biobank without family history.

418 S. Table 3. Associations between GRSs and risk factors of breast cancer in Estonian Biobank.

419 S. Table 4. Associations between GRSs and risk factors of breast cancer in UK Biobank.

420 In the “Additional file 2” are Supplementary Figures and Methods in *.doc format. There are
 421 two supplementary Files and detailed information about genotyping, quality control, GWAS
 422 data management and statistical modelling for breast cancer risk factors and GRSs. The
 423 Supplementary figures are following:

424 Figure S1. Associations of GRSs with prevalent breast cancer in EstBB data.

425 Figure S2. Correlations between different genetic risk scores (GRSs).